$0.85
4.72%
Nasdaq, Wed, Sep 30 2026.
ISIN
US62856X1028
Symbol
TNFA

MyMD Pharmaceuticals Inc Stock price

$0.85
-1.47 63.31% 1M
-2.39 73.73% 6M
-3.14 78.67% YTD
-3.30 79.49% 1Y
-1,754.15 99.95% 3Y
-21,599.15 100.00% 5Y
-3,869,451.95 100.00% 10Y
-54,812,159.15 100.00% 20Y
Nasdaq, Closing price Wed, Sep 30 2026
-0.04 4.72%
ISIN
US62856X1028
Symbol
TNFA
Industry

Is MyMD Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,120 stocks worldwide.

Key metrics

Basic
Market capitalization
-
Enterprise Value
-
Net debt
-
Cash
-
Shares outstanding
-
Valuation (TTM | estimate)
P/E
negative
P/S
- | -
EV/Sales
- | -
EV/FCF
-
P/B
-
Financial Health
Equity Ratio
83.8%
Return on Equity
-103.4%
ROCE
-
ROIC
-
Debt/Equity
-
Financials (TTM | estimate)
Revenue
- | -
EBITDA
-
EBIT
-
Net Income
-
Free Cash Flow
-
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-
EBIT
-
Net Income
-
Free Cash Flow
-
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow
-
More
EPS
-
FCF per Share
-
Short interest
16.9%
Employees
-
Rev per Employee
-

MyMD Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a MyMD Pharmaceuticals Inc forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a MyMD Pharmaceuticals Inc forecast:

Buy
86%
Hold
14%

Financial data from MyMD Pharmaceuticals Inc

Sep '23
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 7.89 7.89
18% 18%
-
- Research and Development Expense 7.37 7.37
7% 7%
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -16 -16
5% 5%
-
Net Profit -7.08 -7.08
52% 52%
-

In millions USD.

Don't miss a Thing! We will send you all news about MyMD Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

MyMD Pharmaceuticals, Inc. is a clinical stage pharmaceutical company which engages in extending healthy lifespan. It involves in developing and commercializing therapeutic platforms based on well-defined therapeutic targets, MYMD-1 and Supera-CBD. The company is headquartered in Baltimore, MD.

Head office United States
CEO Christopher Chapman
Founded 1989
Website tnfpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today